229 related articles for article (PubMed ID: 23008829)
1. [Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Török S; Cserepes T M; Rényi-Vámos F; Döme B
Magy Onkol; 2012 Sep; 56(3):199-208. PubMed ID: 23008829
[TBL] [Abstract][Full Text] [Related]
2. [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Török S; Döme B
Magy Onkol; 2012 Mar; 56(1):3-15. PubMed ID: 22403757
[TBL] [Abstract][Full Text] [Related]
3. Novel molecular targeted therapies for refractory thyroid cancer.
Perez CA; Santos ES; Arango BA; Raez LE; Cohen EE
Head Neck; 2012 May; 34(5):736-45. PubMed ID: 21544895
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors and the thyroid.
Sherman SI
Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23(6):713-22. PubMed ID: 19942148
[TBL] [Abstract][Full Text] [Related]
5. What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?
Capdevila J; Carrato A; Tabernero J; Grande E
Crit Rev Oncol Hematol; 2014 Nov; 92(2):83-106. PubMed ID: 24924525
[TBL] [Abstract][Full Text] [Related]
6. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
7. Rationale and clinical results of multi-target treatments in oncology.
Sartore-Bianchi A; Ricotta R; Cerea G; Maugeri MR; Siena S
Int J Biol Markers; 2007; 22(1 Suppl 4):S77-87. PubMed ID: 17520585
[TBL] [Abstract][Full Text] [Related]
8. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
Hilberg F; Roth GJ; Krssak M; Kautschitsch S; Sommergruber W; Tontsch-Grunt U; Garin-Chesa P; Bader G; Zoephel A; Quant J; Heckel A; Rettig WJ
Cancer Res; 2008 Jun; 68(12):4774-82. PubMed ID: 18559524
[TBL] [Abstract][Full Text] [Related]
9. Early clinical studies of novel therapies for thyroid cancers.
Sherman SI
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):511-24, xi. PubMed ID: 18502340
[TBL] [Abstract][Full Text] [Related]
10. [Oral drugs inhibiting the VEGF pathway].
Ropert S; Mir O; Armand JP
Bull Cancer; 2007 Jul; 94 Spec No():S180-90. PubMed ID: 17846003
[TBL] [Abstract][Full Text] [Related]
11. [Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Döme B; Magyar M
Magy Onkol; 2008 Sep; 52(3):247-59. PubMed ID: 18845495
[TBL] [Abstract][Full Text] [Related]
12. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.
Kutluk Cenik B; Ostapoff KT; Gerber DE; Brekken RA
Mol Cancer Ther; 2013 Jun; 12(6):992-1001. PubMed ID: 23729403
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Lee CB; Socinski MA
Rev Recent Clin Trials; 2007 May; 2(2):117-20. PubMed ID: 18473996
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib.
Rini BI
Expert Opin Pharmacother; 2006 Mar; 7(4):453-61. PubMed ID: 16503817
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Hong S; Tan M; Wang S; Luo S; Chen Y; Zhang L
J Cancer Res Clin Oncol; 2015 May; 141(5):909-21. PubMed ID: 25373315
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
18. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Petrelli A; Giordano S
Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997
[TBL] [Abstract][Full Text] [Related]
19. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA
Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862
[TBL] [Abstract][Full Text] [Related]
20. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]